Eli Lilly and Company $LLY Stock Holdings Boosted by J.Safra Asset Management Corp

J.Safra Asset Management Corp boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,918 shares of the company's stock after purchasing an additional 1,247 shares during the period. J.Safra Asset Management Corp's holdings in Eli Lilly and Company were worth $8,298,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Willner & Heller LLC grew its holdings in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after acquiring an additional 9 shares during the last quarter. Aspiring Ventures LLC boosted its holdings in shares of Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock worth $306,000 after buying an additional 9 shares during the period. Morey & Quinn Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after buying an additional 10 shares during the period. Wealthspan Partners LLC increased its position in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after acquiring an additional 10 shares in the last quarter. Finally, G&S Capital LLC increased its position in shares of Eli Lilly and Company by 2.0% in the fourth quarter. G&S Capital LLC now owns 501 shares of the company's stock worth $538,000 after acquiring an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 1.0%

Eli Lilly and Company stock opened at $1,257.26 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $694.23 and a fifty-two week high of $1,292.65. The firm has a fifty day moving average price of $1,180.14 and a two-hundred day moving average price of $1,059.82. The firm has a market cap of $1.18 trillion, a price-to-earnings ratio of 42.19, a P/E/G ratio of 1.47 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the business posted $6.31 earnings per share. The firm's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is 23.22%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LLY. Citigroup lifted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Royal Bank Of Canada raised their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research report on Wednesday, July 8th. Finally, Wolfe Research restated an "outperform" rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source